Biopharma financings saw their third highest year, with companies collectively raising $102.15 billion in 2024, behind only 2020 and 2021. The amount marked a 44% jump from $70.97 billion in financings in 2023 and a 68% increase from $60.81 billion in 2022. The fourth quarter (Q4) contributed $15.45 billion, the lowest quarter of the year, following $16.38 billion in Q3, $23.07 billion in Q2, and a strong $47.25 billion in Q1.

Nobi BV secured €35 million (US$37 million) in an oversubscribed series B financing round to develop its artificial intelligence (AI)-powered smartlights which can detect falls in the elderly.

Atalanta Therapeutics Inc. has completed a $97 million series B financing to support its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease toward IND filings this year and through clinical proof of concept.

With multiple large M&A deals already announced in January, CEOs of major med-tech companies outlining acquisition plans for 2025 and declining interest rates, the stage is set for a significantly more active year of M&A. Financings, too, have ticked up and analysts expect the trend to continue, offering hope for a positive year for the med-tech industry.

Neko Health AB raised $260 million in its series B funding round to expand the reach of its artificial intelligence (AI)-driven full body scanning technology to meet growing demand. The fund raise comes amid an increasing shift in behaviors towards more preventative measures in health care in a bid to remove the risk of developing chronic diseases.